Literature DB >> 25733706

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

Clint T Allen1, Barbara Conley2, John B Sunwoo3, Carter Van Waes4.   

Abstract

In a study published in the May 1, 2001, issue of Clinical Cancer Research, Sunwoo and colleagues provided evidence for proteasome inhibition of NF-κB and tumorigenesis, supporting early-phase clinical trials in solid malignancies of the upper aerodigestive tract. Subsequent clinical studies uncovered a dichotomy of responses in patients with hematopoietic and solid malignancies, and the mechanisms of resistance. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25733706      PMCID： PMC4351792          DOI： 10.1158/1078-0432.CCR-14-2550

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Authors:  J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Bortezomib: understanding the mechanism of action.

Authors:  Bilal Piperdi; Yi-He Ling; Leonard Liebes; Franco Muggia; Roman Perez-Soler
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

Review 3.  Targeting the ubiquitin+proteasome system in solid tumors.

Authors:  James J Driscoll; E Steve Woodle
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 4.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

5.  Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Authors:  Athanassios Argiris; Austin G Duffy; Shivaani Kummar; Nicole L Simone; Yoshio Arai; Seungwon W Kim; Susan F Rudy; Vishnu R Kannabiran; Xinping Yang; Minyoung Jang; Zhong Chen; Nanette Suksta; Theresa Cooley-Zgela; Susmita G Ramanand; Aarif Ahsan; Mukesh K Nyati; John J Wright; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

Review 6.  NF-κB and the link between inflammation and cancer.

Authors:  Joseph A DiDonato; Frank Mercurio; Michael Karin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

7.  Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Authors:  Carter Van Waes; Angela A Chang; Peter F Lebowitz; Colleen H Druzgal; Zhong Chen; Yusri A Elsayed; John B Sunwoo; Susan F Rudy; John C Morris; James B Mitchell; Kevin Camphausen; David Gius; Julian Adams; Edward A Sausville; Barbara A Conley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-11       Impact factor: 7.038

8.  Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Authors:  Clint Allen; Kunal Saigal; Liesl Nottingham; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

9.  Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Authors:  Zhong Chen; Justin L Ricker; Pramit S Malhotra; Liesl Nottingham; Lorena Bagain; Tin Lap Lee; Ning T Yeh; Carter Van Waes
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

10.  Targeting NF-κB in mouse models of lung adenocarcinoma.

Authors:  Carter Van Waes
Journal:  Cancer Discov       Date:  2011-08       Impact factor: 39.397
  10 in total
  4 in total

Review 1.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

2.  Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.

Authors:  Jennifer L Wilson; Eirini Kefaloyianni; Lauren Stopfer; Christina Harrison; Venkata S Sabbisetti; Ernest Fraenkel; Douglas A Lauffenburger; Andreas Herrlich
Journal:  Mol Cancer Res       Date:  2017-10-10       Impact factor: 5.852

3.  Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.

Authors:  Naoki Suenaga; Mimi Kuramitsu; Kanae Komure; Ayumi Kanemaru; Kanako Takano; Kazuya Ozeki; Yuka Nishimura; Ryoji Yoshida; Hideki Nakayama; Satoru Shinriki; Hideyuki Saito; Hirofumi Jono
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

4.  Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells.

Authors:  Nan-Xiang Chen; Kun Liu; Xuan Liu; Xin-Xin Zhang; Dong-Yi Han
Journal:  Med Sci Monit       Date:  2020-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.